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Use of Self-Expanding Stents for the
Treatment of Vertebral Artery Ostial
Stenosis: a Single Center Experience
Objective: To evaluate our early experience using self-expanding stents to
treat atherosclerotic vertebral artery ostial stenosis (VAOS), with respect to tech-
nical feasibility and clinical and imaging follow-up results.
Materials and Methods: A total of 20 lesions in 20 patients underwent stenting
of the VAOS using a self-expanding stent (Precise RX; Cordis Neurovascular,
Miami Lakes, FL). Two patients were asymptomatic. We analyzed the technical
success rate, causes of technical failure, occurrence of any vascular or neurologi-
cal event, and the occurrence of any neurological abnormality or in-stent resteno-
sis (ISR) seen on follow-up. The imaging follow-up was performed with Doppler
ultrasound (DUS) as a primary screening modality.
Results: One instance of technical failure was caused by failure of the
guidewire passage. The stent diameter was 5 mm, and post-stenting balloon
dilatations were necessary in all cases. Stent misplacement requiring placement
of an additional stent occurred in four cases. Following a 14.8 month average
clinical follow-up time, two patients showed anterior circulation ischemia, which
was not attributed to the VAOS we treated. Following a 13.7 month average DUS
follow-up, five patients showed a mild degree of diffuse or focal intimal thickening
in the stent lumen; however, none of the stenosis showed luminal loss of more
than 50% and no stent fracture was noted. 
Conclusion: The use of self-expanding stents for treating VAOS was techni-
cally feasible and helped to improve artery patency during our limited follow-up
interval. 
therosclerotic stenosis of the vertebral artery (VA) at the ostium is not a
rare clinical condition and has been considered clinically benign (1). With
the frequent use of CT angiography (CTA) or MR angiography (MRA),
an increasing number of lesions have recently been discovered. According to the New
England Medical Center Posterior Circulation Registry, contrary to the generally
accepted notion, approximately one-third of the patients with posterior circulation
ischemia had VA ostial stenosis (VAOS) (2, 3). It is generally believed that the main
mechanism of ischemia with VAOS is artery-to-artery embolism (2-5). 
Vertebral artery ostial stenosis has been treated medically and intervention has been
indicated only in selected patients. Surgery, such as VA-common carotid artery
transposition, was performed on very rare occasions until it was replaced by endovas-
cular techniques such as a balloon angioplasty or stent replacement (6-12).
As was already reported by the CAVATAS (carotid and vertebral artery translumi-
nal angioplasty study) trial, angioplasty and/or stenting of VAOS was feasible but
showed a high restenosis rate. Several case-series studies have reported higher techni-
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Acal success rates (95-100%) with relatively high in-stent
restenosis (ISR) rates (20-50%) seen on follow-up (7-10,
13). Although symptomatic ISR is relatively rare, its
occurrence rate can be disappointing, thus making it
tempting to use drug-eluting stents (14, 15). With the drug-
eluting stents, the ISR rate has decreased significantly;
however, the procedures were not free from occasional
stent fractures which were already seen with balloon-
expandable stents (BES) in VAOS (16, 17).
As had already been suggested by Weber et al. (12), we
also felt the need for a new technical approach for treating
this particular lesion. Due to our continuing accumulation of
experience with self-expanding carotid stents, we assumed
that the physical properties of a self-expanding stent (SES),
such as its longitudinal, radial, and rotational flexibility and
its continuous radial expansile force, might help to adjust to
the peculiar anatomical environment of a VAOS.
Therefore, the purpose of our report is to analyze our
experience with SES for the endovascular treatment of
atherosclerotic VAOS with respect to technical feasibility,
immediate clinical and angiographic outcomes, and clinical
and imaging follow-up outcomes.
MATERIALS AND METHODS
Patient Population and Indications
From our neurointerventional patient database, we
extracted a total of 20 patients who had undergone stent-
assisted revascularization of VAOS or proximal VA stenosis
from December 2003 to April 2008. All patients were men
whose average age was 64.3 years, with a range of 47 to 74
years. Among these patients, nine presented with an acute
stroke in the posterior circulation, whereas the nine others
presented with symptoms of vertebrobasilar insufficiency
without any notable brain parenchymal lesion seen on the
imaging studies. Lesions were incidentally discovered
during vascular evaluation of coexisting internal carotid
artery disease in two patients. Diagnosis of the VA stenosis
was initially assessed by MRA, and the lesion characteristics
were further evaluated by way of a digital subtraction
angiography (DSA) in all patients. The site of stenosis was
at the ostium in 17 patients and in the proximal VA before
entering the transverse foramen without involvement of the
ostium in three patients. The mean diameter of the target
vessel in the distal sound segment was 3.9 (2.9-5.2) mm.
The mean degree of stenosis before the procedure was 73%
(56-91%). The mean length of stenosis was 7.7 (3-25) mm.
Indications for stent implantation included symptomatic
stenosis with more than 50%, or asymptomatic lesion with
significant stenosis of the dominant VA in patient with
bilateral stenoses, or asymptomatic unilateral significant
stenosis with a- or hypo-plastic contralateral VA which
includes a small VA with a posterior inferior cerebellar
artery ending. The significant stenosis was defined as more
than 70% of stenosis. The degree of stenosis was calculated
using following formula: [1 - (diameter of stenotic segment /
distal vessel diameter avoiding poststenotic dilatation)] ×
100 (%).
Stent Implantation
For the elective procedures, the patients were pretreated
with aspirin (100 mg daily following a 500- or 300-mg
loading dose) and clopidogrel (75 mg daily following a 300-
mg loading dose) for 2-5 days before the procedure. In an
acute setting, the loading doses of clopidogrel and aspirin
were administered via a nasogastric tube immediately
before the procedure or stent implantation. Informed
consent was obtained from each patient or relative. Under
local anesthesia, the patient was anticoagulated with
intravenous heparin after obtaining diagnostic angiograms
of both the cerebral arteries and the stenotic VA. The
heparin dose was adjusted to achieve an ACT (activated
clotting time) of 2-2.5 times that of the baseline. A 6-Fr
long sheath (COOK Shuttle Bloomington, IN) or an 8-Fr
guiding catheter (Envoy; Cordis Neurovascular, Miami
Lakes, FL) was introduced into the proximal subclavian
artery. If the position of the tip of the guiding catheter was
unstable, insertion of an additional sturdy guidewire
(Glidewire; Boston Scientific Corp., Fremont, CA) as a
‘buddy’ wire far into the ipsilateral brachial artery was
helpful for the maintenance of guiding catheter stability
during the procedure. The lesion was crossed using a
microguidewire (Transend Floppy 300; Boston Scientific
Corp.). In some cases, it was necessary to use a
microcatheter due to the difficulty of the lesion cross. The
lesion was predilated using a 2.0-3.0-mm (Maverick;
Boston Scientific Corp.) or 4-mm-diameter (Ultrasoft;
Boston Scientific Corp.) balloon angioplasty catheter. After
ballooning, a self-expanding stent (Precise RX; Cordis
Neurovascular) was deployed (Fig. 1). We attempted to
minimize redundancy of the proximal segment of the stent
within the subclavian artery; however, we were not always
successful. Post-dilation was performed using a 4- or 5-mm-
diamater angioplasty balloon catheter (Ultrasoft; Boston
Scientific Corp.). The placement of an anti-embolic distal
protection device was not part of our routine procedure.
Clinical and Radiological Follow-Up
After the procedure, the patient was transferred to the
neuro-intensive care unit for overnight observation in the
event of any vascular or nonvascular adverse reaction.
Patients were educated and medicated in order to, as much
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Clinical and radiological follow-ups were scheduled at 3, 6,
and 12 months after the procedure and annually thereafter.
For the imaging follow-up, we performed a duplex
ultrasound to evaluate stent patency due to its availability
and non-invasiveness. DSA was reserved for the patients
who showed significant ISR on Doppler ultrasound (DUS).
Analysis
We analyzed the technical success rate, which was defined
as the successful delivery of the stent to the target lesion
without significant residual stenosis. The cause of technical
failure was identified. We found that the most difficult step of
the procedure was the exact deployment of the stent along
with sufficient covering of the lesion. We analyzed the rate of
stent misplacement which required another stent placement.
The degree of residual stenosis was calculated again immedi-
ately after the procedure. We analyzed the occurrence of
acute in-stent thrombosis or distal embolization as well as
any vascular or neurological event. The clinical and
radiologic follow-up results were analyzed for the occurrence
of any neurological abnormality or ISR. Significant ISR was
defined as a greater than 50% diameter narrowing. Since
there is a lack of solid DUS criteria for the significant ISR, we
relied mostly on the presence and degree of intimal thicken-
ing on the gray scale images. We graded the degree of intimal
thickening as mild (less than 30% of luminal loss), moderate
(less than 50% of luminal loss) and severe (more than 50%
of luminal loss). Patterns of the intimal thickening were classi-
fied as diffuse or focal and peak systolic flow velocities were
measured from the multiple points in the stented segment
and the highest value was recorded to use as an ancillary
finding in the estimation of the significance of the lumen loss.
Stent mesh integrity was evaluated with the DUS.
RESULTS
The technical success rate for stent placement was 95%.
One case of technical failure occurred as a result of a
failure in the guidewire passage through the stenosis. Data
on each patient were summarized in the Table 1, which
includes the summary of the data from the 19 patients who
underwent successful stent placement. Stent diameter was
5 mm in most cases, and the length of the stent ranged
from 20 to 50 mm. A second stent was required in four
patients because of the misplacement of the first stent. The
main cause of misplacement was distal jumping of the
stent, thereby failing to cover the most stenotic portion of
the lesion, which was at the os. Post-balloon dilation was
required in all cases because of the significant residual
stenosis, even after stent placement. After post-dilation,
there was no significant residual stenosis in all cases,
Chung et al.
158 Korean J Radiol 11(2), Mar/Apr 2010
Table 1. Summary of 20 Patients
Lesion 
Parent Artery 
Stenosis 
Stent 
Additional
Residual  DUS FU 
Number Age Sex
Location
Presentation Diameter 
(%)
Predilatation Size 
Stent
Stenosis  Interval 
(mm) (mm) (%) (months)
01 65 M Both VA, osAcute Infarction 3.6  66.7  Yes 5*50 No 15 13.1 
02 74 M Left VA, osAcute Infarction 4.3  58.1  No 5*20 Yes 00 12.5 
03 65 M Left VA, proximal VBI 4.8  62.5  Yes5*30 No 20 03.1 
04 56 M Left VA, osAcute Infarction 2.9  65.5  No 5*20 No 00 06.1 
05 63 M Right VA, osAcute Infarction 3.5  91.4  No 5*30 Yes 06 08.1 
06 56 M Left VA, osAcute Infarction 4.0  90.0  Yes 5*30 No 08 08.0 
07 47 M Left VA, osAcute Infarction 3.1  67.7  Yes 5*30 No 00 18.3 
08 66 M Right VA, osVBI 2.9  86.2  Yes 5*30 No 00 04.2 
09 67 M Both VA, osIncidental  4.5  77.8  Yes5*20 No 00 05.9 
10 71 M Left VA, osVBI 4.5  55.6  Yes 6*30 No 00 20.9 
11 74 M Right VA, proximal VBI 3.6  66.7  Yes5*30 No 00 12.9 
12 59 M Left VA, osVBI 3.6  60.6  Yes 5*40 Yes 16 18.5 
13 73 M Left VA, osVBI 4.8  58.3  No 5*20 No 10 19.0 
14 60 M Left VA, osVBI 4.0  75.0  Yes 5*30 No 16 21.1 
15 57 M Both VA, osAs ymptomatic 2.5  68.0  Yes 5*30 No 00 29.1 
16 68 M Left VA, osAcute Infarction 4.0  87.5  Yes 5*30 No 25 39.2 
17 61 M Left VA, osAcute Infarction 5.2  73.1  Yes 6*20 Yes 03 12.9 
18 65 M Left VA, osVBI 3.8  84.5  NA NA NA NA NA
19 66 M Both VA, osVBI 3.6  86.1  Yes 5*20 No 00 05.1 
20 72 M Left VA, proximal Acute Infarction 4.4  70.5  Yes5*30 No 11 03.2 
Note.─ DUS FU = Doppler ultrasound follow-up, VA = vertebral artery, VBI = vertebrobasilar insufficiency, Stent size = diameter * length, NA = not applicableleaving a mean residual stenosis rate of 7% and a range of
0-25%. There was no case of acute in-stent thrombosis at
the completion of the procedure. Furthermore, there was
no case of any neurologic abnormality after the procedure.
Two patients showed unexplained blood pressure fluctua-
tion immediately after the procedure; however, they were
stabilized without any subsequent clinical consequences.
A final clinical and imaging follow-up was obtained at an
average of 14.8 (range, 3.2-40.9) months and 13.7 (range,
3.1 to 39.2) months after the procedure, respectively. Two
of the 19 patients showed neurological abnormalities during
the follow-up period. However, their symptoms were not
attributed to the VAOS that was treated. In one patient who
was suffering from underlying lymphoma, recurrent infarc-
tion in the anterior circulation territory was present, and
there were recurrent transient ischemic attacks in the carotid
artery territory in the other patient who had metastatic
disease of an unknown primary origin. On follow-up DUS,
the stented segment, was successfully visualized in all cases
and showed mild degree (less than 30% of luminal loss) of
intimal hyperplasia. The pattern of stenosis was diffuse in
three cases and focal in two cases. None of the lesions
showed significant ISR. Further, on Doppler examination,
the mean of the highest peak systolic velocity measured
within the stented segment was 99.5 (46-260) cm/sec. As
the patient who showed a peak systolic velocity of 260
cm/sec did not show any luminal loss on gray scale images,
this could be explained as compensatory increase of the flow
velocity because the stented VA was the only patent supra-
aortic artery in this particular patient. DUS demonstrated
placed stents which remained intact without deformity or
fracture.
DISCUSSION
Like other ostial lesions, such as those in renal or
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Fig. 1. Placement of self-expanding stent in 68-year-old man who presented two weeks before procedure with right side weakness and
ataxia due to multifocal embolic lesions in posterior circulation. 
A. Contrast-enhanced MR angiography shows bilateral ostial stenoses. Left vertebral artery ostial stenosis lesion was considered to be
cause. 
B. Digital subtraction angiography shows focal severe stenosis of ostium. 
C. Lesion is pre-dilated with 4-mm angioplasty balloon. 
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Fig. 1. Placement of self-expanding stent in 68-year-old man who presented two weeks before procedure with right side weakness and
ataxia due to multifocal embolic lesions in posterior circulation. 
D. Self-expanding stent (Cordis Precise RX, 5 mm × 20 mm) is placed over stenotic lesion, which leaves residual stenosis (arrow). 
E. Residual stenosis is successfully dilated using 5-mm balloon angioplasty catheter. 
F. Final control angiogram shows minimal residual stenosis without flow restriction. 
G. Chest radiograph obtained 12 months after procedure shows full expansion of whole stent. 
H. Clinical and Doppler ultrasound follow-up performed 21 months after procedure shows good patency of stent without significant
intimal hyperplasia.
GHcoronary arteries, previous reports indicate that VAOS has
a high risk of ISR. The reported ISR rates with bare-metal
BESs are between 35 and 45% (7, 8, 12, 13, 18, 19),
which is approximately 10-15% greater than the rate with
bare metal stenting in the coronary arteries and much
greater than that after carotid stenting. This is consistent
with the stenting results seen in coronary ostial lesions,
which show almost two-fold higher ISR rates than usual
non-ostial lesions (20, 21, 36). Considering those study
results, our follow-up study showed the best long-term
patency rate and durability. The only difference between
our report and those reports was the type of stent used for
the revascularization (i.e. SES versus BES).
There have been several possible explanations of
frequent ISR in VAOS after BES placement, all of which
attempted to determine the reason based on the peculiar
anatomic characteristics of the lesion. As seen in other
arterial ostia, the one in VA also has a well-developed,
thick tunica media resembling the features of the adjacent
subclavian artery. Therefore, an atherosclerotic lesion in
that region may have a substantial plaque burden because
the lesion is part of the atherosclerotic process involving
the subclavian artery (11). This would basically explain the
disappointing long-term results of conventional balloon
angioplasty and BESs in the treatment of VAOS. In
addition, the tightness of an ostial lesion might make it
refractory to balloon angioplasty due to the frequent
elastic recoil or residual stenosis, even with a stent,
because of the abundance of muscularis and plaque in the
region (7).
Some researchers have emphasized the importance of
the type or the material from which a stent is made. Taylor
et al. (19) reported that the use of a non-cobalt chromium
type of stent, such as a stainless steel stent, showed a signif-
icantly higher rate of ISR on follow-up. They hypothesized
that the thinner struts in the cobalt-chromium type of
stents could reduce ISR.
Another factor to be considered is the continuous
mobility of the subclavian and VA junction, which could
cause a stent to be bent or flexed during motion. The
difference in flexibility between the artery and the stent
might cause continuous irritation of the stented segment
and eventually provoke an excessive intimal response to
the stent or even fracture of the stent itself (22). Chronic
metallic fatigue of the relatively rigid BES, together with
the endless mobility of the region, has seemed to be the
cause of occasional stent fracture, which in turn could be a
cause of early loss of stent patency (17).
Some researchers have approached this situation in a
different way. They have suggested that the hemodynamic
complexity of the acutely angled junction between the
larger subclavian artery and the smaller VA can provoke
change of wall shear, which is believed to be important for
the excessive intimal hyperplasia and aggravation of
atherosclerosis in the stented segment (7, 23, 24).
To overcome the frequent ISR in VAOS, there have
been several reports regarding the application of drug-
eluting stents. With only limited cases, as we have seen in
coronary ostial lesions (21), significant improvement of the
ISR rate as low as 0-7% has been reported (14, 25).
However, those drug treated stents were basically of the
balloon expandable type and were hence not free from
occasional fractures (16).
We believe that the excellent follow-up results with our
cases can be explained by the superior performance of the
SES (Precise RX, Cordis Neurovascular) we used. This
stent is an open-cell type and made of laser-cut nitinol (26,
27). The potential superiority of SESs over BESs may be
related to the difference in their mechanical properties.
The more radial and longitudinal flexibility of the SES may
reveal its superior conformability to the peculiar anatomy
in the VAOS. However, we cannot tell which of the stent’s
characteristics has played the primarily beneficial role as
there could be several possible explanations. Because of
the sufficient radial expansile force of the SES, there is
probably little chance of elastic recoil once the lesion is
fully dilated after a post-stenting balloon angioplasty,
which we performed in every patient. Continuous radial
force might promote the long term patency of the SES as
Wakhloo et al. (28) observed in their experimental study.
Regarding the continuous mobility of the region, the
longitudinal flexibility of the nitinol stent is probably more
adaptable than the rigid, balloon-expandable stent, which
has little flexibility (29). This characteristic might also
explain the absence of stent fractures in our series.
Regarding the diameter of the target vessels, the
currently available self-expanding vascular stents, the
smallest being 5 mm in diameter, were not suitable for
VAOS, since the mean vessel diameter in our series was
3.9 mm. However, owing to the latitude of the self-
expanding nature of the stent in a smaller-diameter artery,
there was no incidence of over-expansion since we used 4-
mm-diameter balloon catheters for post-dilation in smaller
arteries. We believe that obtaining a vessel diameter
greater than 4 mm might help to reduce the ISR, as was
reported in renal ostial stenting cases (24). Nevertheless,
we felt that we also needed smaller diameter stents, e.g.
4.0 or 4.5 mm. In addition, shorter stents, such as a 1.5-cm
length, would help avoid unnecessary stent placement
crossing the C6 transverse foramen.
From a technical viewpoint, differing from the stenting
technique using BESs, placement of SESs can be difficult
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(11) clearly described in their review article, exact
positioning of even a BES to cover an entire lesion, while
minimizing the protrusion of the free struts into the subcla-
vian artery lumen, could be challenging since the VAOS
was usually focal and very tight. To achieve this goal with
an SES is more challenging, which is why we initially
experienced frequent stent misplacements, which required
the use of an additional stent.
The following procedures might help to reduce misplace-
ment of stents (11, 30, 31): (a) Stable positioning of a
guiding catheter with use of a buddy wire if more stability
is required; (b) Not relying on roadmap images for lesion
localization during the stent positioning as lesions are
mobile. The most reliable technique for lesion visualization
is intermittent flushing of the guiding catheter with contrast
medium; (c) Patient breath-hold during unsheathing of the
stent delivery system. General anesthesia should be consid-
ered if the patient is unable to cooperate during the
procedure. In addition, shortening the stent after deploy-
ment should also be considered, although this phenomenon
occurs minimally with laser-cut stents; (d) Stop unsheath-
ing if there is any flaring of the distal stent markers. The
patient should have the freedom to breath and recheck the
position of the stent by a brief flushing with contrast media
since this will be the last opportunity for repositioning the
stent. Next, the patient should perform another breath-
hold and unsheathe the entire stent with no hesitation; (e)
If there is a possibility of misplacement, another option is
to place the stent, while leaving a sufficient proximal free
segment in the subclavian artery lumen, as we usually did
for additional stent placement. We did not observe any
specific problems when using this technique.
Another technical consideration could be the use of distal
protection devices. Actually, we used Filterwire (Boston
Scientific Corp.) in two cases with seemingly very large
plaque burdens. There was not much difficulty in the
placement of the device or in stent deployment; however,
there was a substantial amount of difficulty in post-dilation
and retrieval of the protection device since the proximal
end of the stent protruded into the subclavian artery lumen
where the arterial course was deflected. The proximal
struts of the deployed stent protruding into the subclavian
artery lumen served as an obstacle to passing catheters
through the stent lumen. After this experience, the use of a
distal protection device was no longer part of our routine.
Although, Divani et al. (32) observed the same frequency
and number of captured emboli between stenting in
carotid stenosis and in VAOS, there has not generally been
much concern regarding the distal embolism in VAOS
unlike in carotid stenosis.
Since the occurrence of bilateral VAOS stenoses are
quite common, the choice of a target lesion can be an issue.
Considering the relative benign clinical consequence of
VAOS, we chose symptomatic lesion or dominant VA
lesion as our treatment target in the case of bilateral VAOS
stenoses. However, bilateral stenting could be done if one
cannot tell which lesion was symptomatic or the diameters
of the two VAs were the same.
There are some limitations to our study. First, it was
performed retrospectively and with a relatively small
number of patients. The clinical and imaging follow-up
periods varied despite our planned periodic follow-up
schedule. We also lacked a conventional angiographic
correlation in evaluating stent patency during follow-up,
which may be crucial for the accurate evaluation of ISR.
As far as vascular imaging follow-up is concerned, we
believe DUS can serve as an effective screening tool for
ISR after stenting of VAOS since the role of CTA is still
limited (33, 34). We are not suggesting that DUS can
replace DSA in the evaluation of ISR; however, the
technique was able to determine whether or not there was
significant ISR. Although it has been reported that visual-
ization of V1 segment with DUS could be unsuccessful
occasionally (35), we could examine the stented segment
without much difficulty in all cases since the implanted
stent played as a good anatomic landmark for the clear
visualization of the V1. However, we suggest that a
correlation study with DSA be performed in order to
validate the accuracy of DUS.
In conclusion, the use of self-expanding stents for the
treatment of the VAOS is technically feasible and may help
to improve the long-term patency of the artery during our
limited follow-up interval. However, size limitation of the
currently available stent diameter and occasional misplace-
ment of the stent requiring placement of an additional
stent remained as technical barriers.
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